Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2023, Volume and Issue: 1878(3), P. 188866 - 188866
Published: Feb. 25, 2023
Language: Английский
Earth-Science Reviews, Journal Year: 2016, Volume and Issue: 160, P. 264 - 299
Published: July 30, 2016
Language: Английский
Citations
720
Nature reviews. Cancer, Journal Year: 2022, Volume and Issue: 22(3), P. 174 - 189
Published: Jan. 14, 2022
Language: Английский
Citations
268
Medicinal Research Reviews, Journal Year: 2020, Volume and Issue: 41(3), P. 1622 - 1643
Published: Dec. 11, 2020
Abstract Hypoxia‐inducible factor 1 (HIF‐1) plays an indispensable role in the hypoxic tumor microenvironment. Hypoxia and HIF‐1 are involved multiple aspects of progression, such as metastasis, angiogenesis, immune evasion. In innate adaptive systems, malignant cells avoid their recognition destruction by HIF‐1. Tumor evasion allows cancer to proliferate metastasize is associated with immunotherapy failure chemoresistance. microenvironment, signaling suppresses systems evade attack inducing expression immunosuppressive factors checkpoint molecules, including vascular endothelial growth factor, prostaglandin E 2 , programmed death‐ligand 1/programmed death‐1. Moreover, blocks tumor‐associated antigen presentation via major histocompatibility complex class I chain‐related/natural killer group 2, member D signaling. Tumor‐associated autophagy release tumor‐derived exosomes contribute HIF‐1‐mediated This review focuses on recent findings potential mechanism(s) underlying effect hypoxia The effects autophagy, have been described. Additionally, regulation exosomes, well roles evasion, discussed. study will our understanding leading development effective HIF‐1‐targeting drugs immunotherapies.
Language: Английский
Citations
212
Communications Biology, Journal Year: 2021, Volume and Issue: 4(1)
Published: June 8, 2021
Abstract Small molecule immune checkpoint inhibitors targeting PD-1 and other pathways may offer advantages including ease of dosing, ability to manage immune-related adverse events (irAEs) due their shorter pharmacokinetic exposure opportunity target more than one pathway for improving efficacy. Here we describe the identification characterization CA-170, an amino acid inspired small inhibitor PD-L1 VISTA derived from interface PD-L1. CA-170 exhibited potent rescue proliferation effector functions T cells inhibited by PD-L1/L2 with selectivity over proteins as well a broad panel receptors enzymes. Observed blocking signaling binding in cellular context without preventing assembly PD-1:PD-L1 complex support formation defective ternary mechanism action CA-170. Oral administration resulted increased activation tumor, significant anti-tumor efficacy number immunocompetent mouse tumor models either single agent or combination approved therapeutics. These results prompted advancement human clinical trials.
Language: Английский
Citations
115
Journal of Translational Medicine, Journal Year: 2023, Volume and Issue: 21(1)
Published: Feb. 4, 2023
Abstract Background The systemic immune-inflammation index (SII) is a novel biomarker to predict the prognosis of some malignant tumors based on neutrophil, platelet, and lymphocyte counts. Evidence scarce about prognostic value SII for prostate cancer patients. This systematic review meta-analysis was conducted explore in cancer. Methods PubMed, Embase, Web Science, Cochrane Library (CENTRAL) databases were searched determine eligible studies from inception August 15, 2022. Hazard ratios (HRs) with 95% confidence intervals (CIs) extracted pool results. Statistical analyses by using Stata 17.0 software. Results A total 12 8083 patients included. quantitative synthesis showed that high related poor overall survival (OS) (HR = 1.44, CI 1.23–1.69, p < 0.001). Furthermore, subgroup analysis associated OS groups any ethnicity, tumor type, cutoff value. An increased also inferior progression-free (PFS) 1.80, 1.27–2.56, In analysis, PFS Asian 4.03, 1.07–15.17, 0.04) > 580 1.19, 1.04–1.36, 0.01). Conclusion Based current evidence, pretreatment may be PFS. serve as an important indicator More rigorously designed are needed
Language: Английский
Citations
72
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: Dec. 1, 2023
PD-1 (Programmed Cell Death Protein-1) and PD-L1 Ligand-1) play a crucial role in regulating the immune system preventing autoimmunity. Cancer cells can manipulate this system, allowing them to escape detection promote tumor growth. Therapies targeting PD-1/PD-L1 pathway have transformed cancer treatment demonstrated significant effectiveness against various types. This study delves into structure signaling dynamics of its ligands PD-L1/PD-L2, diverse inhibitors their efficacy, resistance observed some patients. Furthermore, explored challenges associated with inhibitor approach. Recent advancements combination immunotherapy chemotherapy, radiation, surgical procedures enhance patient outcomes also been highlighted. Overall, offers an in-depth overview significance future implications oncology.
Language: Английский
Citations
71
Theranostics, Journal Year: 2023, Volume and Issue: 13(5), P. 1520 - 1544
Published: Jan. 1, 2023
Immunotherapy has achieved great success recently and opened a new avenue for anti-tumor treatment. Programmed cell death 1/programmed ligand 1 (PD-1/PD-L1) are typical immune checkpoints that transmit coinhibitory signals, muting the host immunity. Monoclonal antibodies block PD-1/PD-L1 axis have benefited many patients with different tumor diseases. However, objective response rate is still unsatisfactory. In this review, we summarize three strategies targeting PD-L1 based on forms of various regulating mechanisms to enhance therapeutic effect, including blockade interaction between PD-1, downregulation expression degradation mature PD-L1. Thereinto, describe variety materials been designed target PD-L1, antibodies, nanoparticle, peptide, aptamer, RNA, small molecule. Additionally, list drugs regulation capacity used in clinical ongoing studies explore other alternatives besides anti-PD-L1 monoclonal antibodies. Moreover, discuss associated opportunities cancer combination therapy modalities such as chemotherapy, radiotherapy, photodynamic (PDT) photothermal (PTT), these conventional or emerging capable increasing cells by altering microenvironment (TME), would display synergistic effect. At last, give brief summary outlook regarding research status future prospect immunotherapy.
Language: Английский
Citations
64
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: May 16, 2023
Programmed cell death 1 receptor (PD-1) and its ligands constitute an inhibitory pathway to mediate the mechanism of immune tolerance provide homeostasis. Significantly, binding partners PD-1 associated are diverse, which facilitates immunosuppression in cooperation with other checkpoint proteins. Accumulating evidence has demonstrated important immunosuppressive role axis tumor microenvironment autoimmune diseases. In addition, blockades have been approved treat various cancers, including solid tumors hematological malignancies. Here, we a comprehensive review pathway, focusing on structure expression PD-1, programmed ligand (PD-L1), 2 (PD-L2); diverse biological functions signaling health immune-related diseases (including immunity, autoimmunity, infectious transplantation allergy privilege); adverse events related PD-L1 inhibitors.
Language: Английский
Citations
58
MedComm, Journal Year: 2023, Volume and Issue: 4(1)
Published: Jan. 11, 2023
Cancer is a complex disease associated with combination of abnormal physiological process and exhibiting dysfunctions in multiple systems. To provide effective treatment diagnosis for cancer, current strategies simultaneously focus on various tumor targets. Based the rapid development nanotechnology, nanocarriers have been shown to exhibit excellent potential cancer therapy. Compared nanoparticles single functions, multifunctional are believed be more aggressive potent context targeting. However, not simply an upgraded version original function, but involves sophisticated system proper backbone, optimized modification sites, simple preparation method, efficient function integration. Despite this, many well-designed promising therapeutic emerged recently. Here, give detailed understanding analyzation currently developed nanoparticles, their platform structures organic or inorganic backbones were systemically generalized. We emphasized functionalization strategies, which additional functions nanoparticle. also discussed application that involved nanoformulations functional crosstalk. This review thus provides overview construction advances nanoparticles.
Language: Английский
Citations
45
Cell Reports Medicine, Journal Year: 2024, Volume and Issue: 5(2), P. 101357 - 101357
Published: Jan. 21, 2024
Programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) blockade has become a mainstay of cancer immunotherapy. Targeting the PD-1/PD-L1 axis with small molecules is an attractive approach to enhance antitumor immunity. Here, we identified natural marine product, benzosceptrin C (BC), that enhances cytotoxicity T cells by reducing abundance PD-L1. Furthermore, BC exerts its effect in mice bearing MC38 tumors activating tumor-infiltrating Mechanistic studies suggest can prevent palmitoylation PD-L1 inhibiting DHHC3 enzymatic activity. Subsequently, transferred from membrane cytoplasm and cannot return via recycling endosomes, triggering lysosome-mediated degradation Moreover, combination anti-CTLA4 effectively Our findings reveal previously unrecognized mechanism represent alternative immune checkpoint (ICB) therapeutic strategy efficacy
Language: Английский
Citations
27